| Molecular Simulations, Inc. | |||
| Proposed Ticker: | MSIM | 9685 Scranton Road | |
| Exchange: | NASDAQ-National Market | San Diego, CA 92121 | |
| Industry: | High-Tech (SIC Code 7372) | (619) 458-9990 | |
| Type of Shares: | Common Shares | Filing Date: | 2/10/97 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $11.00 - $13.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 1,435,000 | Expenses: | $650,000 | |
| Secondary Shares: | 1,065,000 | Shares Out After: | 8,045,952 |
| Manager | Tier | Phone |
| Hambrecht & Quist Incorporated | Lead Manager | (415) 439-3626 |
| Adams, Harkness & Hill | Co-manager | (617) 371-3705 |
| Volpe, Welty & Company | Co-manager | (415) 274-4463 |
| Issuer's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm: | Gunderson Dettmer Stough Villeneuve Franklin |
| Auditor: | Arthur Andersen |
| Registrar/Transfer Agent: | Harris Trust Company of California |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $47.26 | Assets: | $41.27 | ||
| Net Income: | $2.60 | Curr Assets: | |||
| EPS: | $0.34 | Liabilities: | $33.88 | ||
| Prior EPS: | -$4.56 | Curr Liabilities: | |||
| Cash Flow/Oper: | $7.75 | Equity: | $7.39 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is the leading provider of molecular modeling and simulation software. The company designs, develops, markets and supports software that facilitates the discovery and development of new products and processes in the pharmaceutical, biotechnology, chemical, petrochemical and materials industries. Using the company's products, researchers are able to increase the speed and efficiency of the research and development cycle, thereby reducing product development costs and shortening the time to market for new product introductions and process improvements. The company's customers comprise leading commercial, governmental and academic organizations, including many of the largest pharmaceutical, biotechnology, chemical, petroleum and semiconductor companies worldwide. The company has a comprehensive product suite consisting of over 100 application modules based on proprietary technologies that employ fundamental scientific principles, advanced computer visualization, molecular modeling techniques and computational chemistry. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for working capital and other general corporate purposes, primarily in the areas of research and development, sales, marketing and customer support. |